Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Early Versus Deferred Standard Androgen Suppression Therapy for Advanced Hormone‐sensitive Prostate Cancer." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438611/all/Antiplatelet_and_anticoagulant_agents_for_secondary_prevention_of_stroke_and_other_thromboembolic_events_in_people_with_antiphospholipid_syndrome_New_search_for_studies_and_content_updated__conclusions_changed_. Accessed 28 March 2024.
Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438611/all/Antiplatelet_and_anticoagulant_agents_for_secondary_prevention_of_stroke_and_other_thromboembolic_events_in_people_with_antiphospholipid_syndrome_New_search_for_studies_and_content_updated__conclusions_changed_. Accessed March 28, 2024.
Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/438611/all/Antiplatelet_and_anticoagulant_agents_for_secondary_prevention_of_stroke_and_other_thromboembolic_events_in_people_with_antiphospholipid_syndrome_New_search_for_studies_and_content_updated__conclusions_changed_
Early Versus Deferred Standard Androgen Suppression Therapy for Advanced Hormone‐sensitive Prostate Cancer [Internet]. In: Cochrane Abstracts. [cited 2024 March 28]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438611/all/Antiplatelet_and_anticoagulant_agents_for_secondary_prevention_of_stroke_and_other_thromboembolic_events_in_people_with_antiphospholipid_syndrome_New_search_for_studies_and_content_updated__conclusions_changed_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer
ID - 438611
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438611/all/Antiplatelet_and_anticoagulant_agents_for_secondary_prevention_of_stroke_and_other_thromboembolic_events_in_people_with_antiphospholipid_syndrome_New_search_for_studies_and_content_updated__conclusions_changed_
DB - Evidence Central
DP - Unbound Medicine
ER -